Arbutus Biopharma Corporation (ABUS)

Over the past six months, Arbutus received U.S. FDA Fast Track Designation for Imdusiran, reported its Fourth Quarter and Year End 2025 Financial Results, announced a $2.25 billion global settlement with Moderna, reported its Third Quarter 2025 Financial Results, and announced that four abstracts were accepted for presentation at AASLD - The Liver Meeting® 2025. The stock has experienced a 34.650% change over the past year, with a 52-week range between $2.94 and $5.10. As of May 8, 2026, the stock traded at $4.35, within a 52-week range of $3.08 to $4.95.

There is no information available to suggest demand seasonality for Arbutus Biopharma Corp.'s products and services. The demand for its therapeutic candidates is driven by medical need and clinical development milestones rather than seasonal patterns.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for infectious diseases, particularly chronic Hepatitis B virus (cHBV) infection, leveraging its expertise in liposomal drug delivery and RNA interference. Its major product pipeline candidates include Imdusiran (AB-729), an RNAi therapeutic candidate in phase 2a clinical trials, and AB-101, an oral PD-L1 inhibitor in phase 1a/1b clinical trials. The company also focuses on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company headquartered in Warminster, Pennsylvania, United States, and develops novel therapeutics for infectious diseases in the United States.

Arbutus Biopharma's brand reputation has been positively influenced by the U.S. FDA Fast Track Designation for Imdusiran, the $2.25 billion global settlement with Moderna, and the presentation of clinical trial data at major scientific conferences. These positive developments suggest a favorable trajectory for its reputation.

Arbutus Biopharma Corporation has significant institutional ownership, with 182 institutional owners and shareholders holding a total of 122,308,228 shares, representing 62.42% of the company's stock. Roivant Sciences Ltd is the largest individual shareholder, owning 38.85 million shares, representing 19.87% of the company. Insider ownership stands at 142.33%, while retail investors hold 0.00%.